Tianeptine5-HT facilitator CAS# 66981-73-5 |
- Granisetron HCl
Catalog No.:BCC1060
CAS No.:107007-99-8
- Vilazodone
Catalog No.:BCC2040
CAS No.:163521-12-8
- SB 271046 hydrochloride
Catalog No.:BCC1924
CAS No.:209481-24-3
- Adoprazine
Catalog No.:BCC1329
CAS No.:222551-17-9
- SEA0400
Catalog No.:BCC1941
CAS No.:223104-29-8
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 66981-73-5 | SDF | Download SDF |
| PubChem ID | 68870 | Appearance | Powder |
| Formula | C21H25ClN2O4S | M.Wt | 436.96 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | 72797-41-2; Tianeptine Acid | ||
| Solubility | Soluble in DMSO | ||
| Chemical Name | 7-[(3-chloro-6-methyl-5,5-dioxo-11H-benzo[c][2,1]benzothiazepin-11-yl)amino]heptanoic acid | ||
| SMILES | CN1C2=CC=CC=C2C(C3=C(S1(=O)=O)C=C(C=C3)Cl)NCCCCCCC(=O)O | ||
| Standard InChIKey | JICJBGPOMZQUBB-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C21H25ClN2O4S/c1-24-18-9-6-5-8-16(18)21(23-13-7-3-2-4-10-20(25)26)17-12-11-15(22)14-19(17)29(24,27)28/h5-6,8-9,11-12,14,21,23H,2-4,7,10,13H2,1H3,(H,25,26) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Tianeptine Dilution Calculator
Tianeptine Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.2885 mL | 11.4427 mL | 22.8854 mL | 45.7708 mL | 57.2135 mL |
| 5 mM | 0.4577 mL | 2.2885 mL | 4.5771 mL | 9.1542 mL | 11.4427 mL |
| 10 mM | 0.2289 mL | 1.1443 mL | 2.2885 mL | 4.5771 mL | 5.7213 mL |
| 50 mM | 0.0458 mL | 0.2289 mL | 0.4577 mL | 0.9154 mL | 1.1443 mL |
| 100 mM | 0.0229 mL | 0.1144 mL | 0.2289 mL | 0.4577 mL | 0.5721 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Tianeptine is a selective facilitator of 5-HT uptake in vitro and in vivo. Tianeptine has no affinity for a wide range of receptors, including 5-HT and dopamine (IC50 > 10 μM) and has no effect on noradrenalin or dopamine uptake. Antidepressant, analgesic and neuroprotective following systemic administration in vivo.
- Beta-Belladonnine
Catalog No.:BCN1893
CAS No.:6696-63-5
- α-Conotoxin PIA
Catalog No.:BCC5976
CAS No.:669050-68-4
- 1,2-O-Isopropylidene-beta-D-fructopyranose
Catalog No.:BCN1383
CAS No.:66900-93-4
- Talniflumate
Catalog No.:BCC7391
CAS No.:66898-62-2
- H-D-Leu-OBzl.HCl
Catalog No.:BCC2682
CAS No.:66866-69-1
- Halobetasol Propionate
Catalog No.:BCC4664
CAS No.:66852-54-8
- LDN 57444
Catalog No.:BCC2087
CAS No.:668467-91-2
- Linagliptin (BI-1356)
Catalog No.:BCC2110
CAS No.:668270-12-0
- Magnoflorine chloride
Catalog No.:BCN2405
CAS No.:6681-18-1
- Jatrorrhizine chloride
Catalog No.:BCN4956
CAS No.:6681-15-8
- Hernandezine
Catalog No.:BCN7793
CAS No.:6681-13-6
- (+/-)-Forbesione
Catalog No.:BCN6423
CAS No.:667914-50-3
- Thiamine hydrochloride
Catalog No.:BCN2225
CAS No.:67-03-8
- EGTA
Catalog No.:BCC7491
CAS No.:67-42-5
- Furazolidone
Catalog No.:BCC8988
CAS No.:67-45-8
- 5-Hydroxymethylfurfural
Catalog No.:BCN4226
CAS No.:67-47-0
- Fluocinolone Acetonide
Catalog No.:BCC4906
CAS No.:67-73-2
- Dicyclomine HCl
Catalog No.:BCC3762
CAS No.:67-92-5
- Vitamin D3
Catalog No.:BCN2186
CAS No.:67-97-0
- Gliotoxin
Catalog No.:BCN3894
CAS No.:67-99-2
- Anthriscusin
Catalog No.:BCN3533
CAS No.:67008-16-6
- Methyl isovanillate
Catalog No.:BCN7960
CAS No.:6702-50-7
- 3,4-Dihydroxy-2-methoxyxanthone
Catalog No.:BCN7631
CAS No.:6702-55-2
- Crenolanib (CP-868596)
Catalog No.:BCC3671
CAS No.:670220-88-9
Anti-osteoporotic effects of an antidepressant tianeptine on ovariectomized rats.[Pubmed:28081469]
Biomed Pharmacother. 2017 Mar;87:575-582.
In the current investigation, the potential alleviating effects of Tianeptine against bone loss induced in ovariectomized (OVX) rats was determined. Two weeks following a bilateral ovariectomy operation, Tianeptine treatment (12.5 and 25mg/kg/twice/d) was initiated and continued for twenty-eight consecutive days. Changes in serum and urinary bone turnover biomarkers and osteoclastogenesis-inducing factors were estimated. The femoral bone mineral content was estimated using inductively-coupled-plasma mass spectrometry. Morphometric alterations of distal femoral bones were observed in the cortical and trabecular structures using micro-CT. Finally, femur bones were assessed for histopathological changes. The lack of estrogen significantly increased the levels of bone turnover biomarkers and inflammatory mediators. Mineral concentrations in the femoral bones were reduced in the OVX group. Furthermore, the femoral bone micro-architecture determined using micro-CT and histopathology were significantly altered by estrogen deficiency. Tianeptine, particularly the higher dose, corrected the elevated levels of bone metabolic products and pro-inflammatory cytokines. Tianeptine also improved mineral concentrations in femoral bones and the disturbed morphometric and histopathological features in OVX rats. In conclusion, Tianeptine alleviated the osteoporotic changes in OVX animals, which may be via inhibition of the hypothalamic-pituitary-adrenal axis stress and osteoclastogenesis-provoking factors, suggesting attenuation of bone matrix degradation and osteoclast stimulation.
The Behavioral Effects of the Antidepressant Tianeptine Require the Mu-Opioid Receptor.[Pubmed:28303899]
Neuropsychopharmacology. 2017 Sep;42(10):2052-2063.
Depression is a debilitating chronic illness that affects around 350 million people worldwide. Current treatments, such as selective serotonin reuptake inhibitors, are not ideal because only a fraction of patients achieve remission. Tianeptine is an effective antidepressant with a previously unknown mechanism of action. We recently reported that Tianeptine is a full agonist at the mu opioid receptor (MOR). Here we demonstrate that the acute and chronic antidepressant-like behavioral effects of Tianeptine in mice require MOR. Interestingly, while Tianeptine also produces many opiate-like behavioral effects such as analgesia and reward, it does not lead to tolerance or withdrawal. Furthermore, the primary metabolite of Tianeptine (MC5), which has a longer half-life, mimics the behavioral effects of Tianeptine in a MOR-dependent fashion. These results point to the possibility that MOR and its downstream signaling cascades may be novel targets for antidepressant drug development.
The effects of desipramine, fluoxetine, or tianeptine on changes in bulbar BDNF levels induced by chronic social instability stress and inflammation.[Pubmed:28359918]
Pharmacol Rep. 2017 Jun;69(3):520-525.
BACKGROUND: Stress is a major predisposing factor in the development of psychiatric disorders and potential source of augmented inflammatory processes in the brain. Increasing body of evidence shows an important role of alterations in the olfactory bulbs (OBs) function in stress-related disorders. The aim of the present study was to investigate the impact of antidepressants on the alterations of brain-derived neurotrophic factor (BDNF) induced by lipopolysaccharide (LPS) in female rats subjected to chronic social instability stress (CSIS). METHODS: 9 weeks old female rats were subjected to CSIS and injected ip once daily with desipramine (10mg/kg), fluoxetine (5mg/kg), or Tianeptine (10mg/kg) for 4 weeks. On the last day of the experiment, rats being at the estrus phase of cycle were injected ip with LPS (1mg/kg) or saline. RESULTS: The BDNF mRNA and protein levels were evaluated in the olfactory bulbs. and the BDNF protein levels were measured in plasma. A single LPS administration in the stressed rats resulted in significant decrease in the bulbar BDNF mRNA, but not in the protein level. Chronic administration of desipramine, fluoxetine, or Tianeptine increased the BDNF mRNA expression and protein levels in the LPS-injected stressed rats. There was no effect of the studied antidepressants on the reduction of the plasma BDNF protein level induced by CSIS and LPS. CONCLUSIONS: These results suggest that studied antidepressants were effective in inhibiting the impact of LPS on BDNF expression in the stressed rats what may be significant for beneficial action of this drugs.
